efavirenz/emtricitabin/tenofovirdisoproxil "laurus" 600+200+245 mg filmovertrukne tabletter
laurus generics gmbh - efavirenz, emtricitabin, tenofovirdisoproxilfumarat - filmovertrukne tabletter - 600+200+245 mg
ictady 245 mg filmovertrukne tabletter
actavis group ptc ehf. - tenofovirdisoproxil-succinat - filmovertrukne tabletter - 245 mg
drelbista 245 mg filmovertrukne tabletter
amneal pharma europe limited - tenofovirdisoproxilfumarat - filmovertrukne tabletter - 245 mg
emtenef 600+200+245 mg filmovertrukne tabletter
stada arzneimittel ag - efavirenz, emtricitabin, tenofovirdisoproxil-succinat - filmovertrukne tabletter - 600+200+245 mg
symtuza
janssen-cilag international nv - darunavir, cobicistat, emtricitabine, tenofovir alafenamide - hiv infektioner - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza er indiceret til behandling af infektion med human immunodeficiency virus type 1 (hiv-1) hos voksne og unge (i alderen 12 år og ældre med kropsvægt mindst 40 kg). genotypic testing should guide the use of symtuza.
duomevolen 200+245 mg filmovertrukne tabletter
amneal pharma europe limited - emtricitabin, tenofovir disoproxilphosphat - filmovertrukne tabletter - 200+245 mg
ictastan 200+245 mg filmovertrukne tabletter
actavis group ptc ehf. - emtricitabin, tenofovirdisoproxil-succinat - filmovertrukne tabletter - 200+245 mg
isentress
merck sharp & dohme b.v. - raltegravir - hiv infektioner - antivirale midler til systemisk anvendelse - isentress er indiceret i kombination med andre antiretrovirale lægemidler til behandling af human immundefekt virus (hiv-1) infektion.
evotaz
bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv infektioner - antivirale midler til systemisk anvendelse - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 og 5.
harvoni
gilead sciences ireland uc - ledipasvir, sofosbuvir - hepatitis c kronisk - antivirale midler til systemisk anvendelse - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 og 5. for at hepatitis c virus (hcv) genotype-specifikke aktivitet, se afsnit 4. 4 og 5.